Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection

Emma S. Winkler, Pavlo Gilchuk, Jinsheng Yu, Adam L. Bailey, Rita E. Chen, Zhenlu Chong, Seth J. Zost, Hyesun Jang, Ying Huang, James D. Allen, James Brett Case, Rachel E. Sutton, Robert H. Carnahan, Tamarand L. Darling, Adrianus C.M. Boon, Matthias Mack, Richard D. Head, Ted M. Ross, James E. Crowe, Michael S. Diamond

Research output: Contribution to journalArticlepeer-review

139 Scopus citations

Abstract

Neutralizing human monoclonal antibodies (mAbs) against SARS-CoV-2 require Fc effector functions for optimal protection during post-exposure therapy, with intact mAbs reducing SARS-CoV-2 burden and lung disease in rodent models better than LALA-PG loss-of-function Fc variant mAbs and requiring monocytes and CD8+ T cells for optimal clinical and virological benefit.

Original languageEnglish
Pages (from-to)1804-1820.e16
JournalCell
Volume184
Issue number7
DOIs
StatePublished - Apr 1 2021

Keywords

  • CD8+ T cells
  • RNA sequencing
  • SARS-CoV-2
  • antibody
  • effector function
  • lung
  • monocytes
  • mouse model
  • pathogenesis
  • therapy

Fingerprint

Dive into the research topics of 'Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection'. Together they form a unique fingerprint.

Cite this